Carregant...

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has conseque...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ellis, Leigh, Pili, Roberto
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3000686/
https://ncbi.nlm.nih.gov/pubmed/21151768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph3082441
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!